- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Cranial nerve disorder.
Displaying page 1 of 1.
EudraCT Number: 2009-018143-25 | Sponsor Protocol Number: 2010 | Start Date*: 2010-05-06 | ||||||||||||||||
Sponsor Name:Västra Götalandsregionen | ||||||||||||||||||
Full Title: An open label, historical control, study to assess the impact on bacteriological healing of Prednisolone in patients with neuroborreliosis-caused peripheral facial palsy receiving treatment with Do... | ||||||||||||||||||
Medical condition: Facialispares orsakad av CNS-infektion med Borrelia burgdorferi. (Neuroborrelios-orsakad facialispares) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016982-26 | Sponsor Protocol Number: ST200-ODU-09-01 | Start Date*: 2010-11-04 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: Neuronal conduction along the visual patways after oral treatment with Acetyl-L-carnitine in patients with Leber’s Hereditary Optic Neuropathy | |||||||||||||
Medical condition: Leber’s Hereditary Optic Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002303-14 | Sponsor Protocol Number: A5951110 | Start Date*: 2008-12-17 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA | |||||||||||||
Full Title: PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER | |||||||||||||
Medical condition: This study is designed to understand the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for two months or longer for the developmen... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002679-42 | Sponsor Protocol Number: SNT-II-003 | Start Date*: 2006-11-22 |
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | ||
Full Title: A double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of patients with Leber's Hereditary Optic Neuropathy | ||
Medical condition: Leber's Hereditary Optic Neuropathy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004696-12 | Sponsor Protocol Number: FACIALPARALYSIS | Start Date*: 2020-01-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis | |||||||||||||
Medical condition: hemifacial paralysis (3 to 6 of the House-Brackmann scale) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003475-11 | Sponsor Protocol Number: UCL/11/0083 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:University College London (UCL) | |||||||||||||
Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis | |||||||||||||
Medical condition: Acute demyelinating optic neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001338-32 | Sponsor Protocol Number: NFPA12 | Start Date*: 2012-09-24 | |||||||||||
Sponsor Name:St. Olavs Hospital Trondheim University Hospital | |||||||||||||
Full Title: Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs) - a randomized controlled trial. The efficacy of cabergoline on tumour volume in previously untreated macroadenomas or resid... | |||||||||||||
Medical condition: non-functioning pituitary adenomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023963-16 | Sponsor Protocol Number: 1014802/202 | Start Date*: 2012-01-05 | |||||||||||
Sponsor Name:Convergence Pharmaceuticals Ltd | |||||||||||||
Full Title: A Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuragia | |||||||||||||
Medical condition: Trigeminal neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) DK (Completed) IT (Completed) ES (Completed) LV (Completed) LT (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004226-25 | Sponsor Protocol Number: 07/O21 | Start Date*: 2008-03-28 | |||||||||||
Sponsor Name:UCL [...] | |||||||||||||
Full Title: Low-dose intravenous immunoglobulin or 0.9% saline in the treatment of trigeminal neuralgia refractory to carbamazepine – a randomized double blind parallel placebo-controlled multicentre trial in ... | |||||||||||||
Medical condition: Trigeminal neuralgia is a severe neuropathic facial pain that currently can often not be well controlled pharmacologically. The gold standard for medical treatment remains carbamazepine, which may ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002473-35 | Sponsor Protocol Number: 802NP302 | Start Date*: 2017-05-19 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia | |||||||||||||
Medical condition: Trigeminal Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001449-16 | Sponsor Protocol Number: 802NP301 | Start Date*: 2017-04-11 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia | |||||||||||||
Medical condition: Trigeminal Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) DK (Prematurely Ended) BE (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000206-28 | Sponsor Protocol Number: SB-318-1502 | Start Date*: 2018-08-14 | |||||||||||
Sponsor Name:Sangamo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis I (MPS I) | |||||||||||||
Medical condition: Mucopolysaccharidosis type I (MPS I) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001758-14 | Sponsor Protocol Number: 201677 | Start Date*: 2015-12-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis | |||||||||||||
Medical condition: Giant Cell Arteritis (GCA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
